- Pivotal Data Show Topical Treatment Delivered Statistically Significant Results, Meeting All Primary and Secondary Endpoints
- Aclaris to Submit New Drug Application to FDA in 1Q17
Aclaris is up more than 22% since it announced the success of two pivotal phase III trials for its skin lesion drug.
Aclaris has surged since the success of two pivotal phase III trials for its lead product candidate for treating skin lesions. The Aclaris CEO says that is only the beginning.
Insiders at these companies have been scooping up shares of their own stock lately. Here's how to trade them from here.